BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression

BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression

Background Cancer immunotherapy has revolutionized cancer treatment. However, considering the limited success of immunotherapy to only some cancer types and patient cohorts, there is an unmet need for developing new treatments that will result in higher response rates in patients with cancer. Immuno...

Full description

Bibliographic Details
Main Authors: Frank Nestle, Ilana Mandel, Dana Haves Ziv, Ilana Goldshtein, Tsuri Peretz, Dror Alishekevitz, Anna Fridman Dror, Motti Hakim, Sharon Hashmueli, Itay Friedman, Yair Sapir, Rita Greco, Hongjing Qu, Dmitri Wiederschain, Lily Pao, Sharad Sharma, Tehila Ben Moshe
Format: Article
Language:English
Published: BMJ Publishing Group 2022-09-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/9/e004859.full

Internet

https://jitc.bmj.com/content/10/9/e004859.full

Similar Items